Research programme: antiviral therapeutics - Ennaid Therapeutics
Latest Information Update: 08 Apr 2020
At a glance
- Originator Ennaid Therapeutics
- Class Antivirals; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Dengue; Encephalitis; Hepatitis C; West Nile virus infections; Yellow fever; Zika virus infection
Most Recent Events
- 02 Apr 2020 Suspended - Preclinical for Dengue in USA (Parenteral) for strategic diversion of focus on COVID-2019 therapeutic
- 02 Apr 2020 Suspended - Preclinical for Encephalitis in USA (Parenteral) for strategic diversion of focus on COVID-2019 therapeutic
- 02 Apr 2020 Suspended - Preclinical for Hepatitis C in USA (Parenteral) for strategic diversion of focus on COVID-2019 therapeutic
Development Overview
Introduction
Ennaid Therapeutics was developing peptide fusion inhibitors for the prevention and treatment of mosquito-borne flavivirus infections, including dengue, West Nile and Zika virus infections, Hepatitis C, Yellow fever, tick-borne encephalitis, Japanese encephalitis, European encephalitis and Kyasanur Forest virus. These peptide's stem mimic the stem of several flavivirus, thus inhibiting viral infections. Preclinical development was underway in the US. However, in April 2020, Ennaid reported that it was putting development in these indications on hold, to switch strategic focus on the development of COVID-2019 therapeutic [1] .
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class Antivirals, Peptides
- Mechanism of Action Immunostimulants
-
WHO ATC code
J05 (Antivirals for Systemic Use)
J05A-P (Antivirals for treatment of HCV infections)
-
EPhMRA code
J5 (Antivirals for Systemic Use)
J5B (Antivirals, excluding anti-HIV products)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Dengue | prevention and treatment | - | Suspended (Preclinical) | USA | Parenteral / unspecified | Ennaid Therapeutics | 02 Apr 2020 |
| Encephalitis | tick-borne encephalitis, Japanese encephalitis, European encephalitis, and Kyasanur Forest virusprevention and treatment | - | Suspended (Preclinical) | USA | Parenteral / unspecified | Ennaid Therapeutics | 02 Apr 2020 |
| Hepatitis C | prevention and treatment | - | Suspended (Preclinical) | USA | Parenteral / unspecified | Ennaid Therapeutics | 02 Apr 2020 |
| West Nile virus infections | prevention and treatment | - | Suspended (Preclinical) | USA | Parenteral / unspecified | Ennaid Therapeutics | 02 Apr 2020 |
| Yellow fever | prevention and treatment | - | Suspended (Preclinical) | USA | Parenteral / unspecified | Ennaid Therapeutics | 02 Apr 2020 |
| Zika virus infection | prevention and treatment | - | Suspended (Preclinical) | USA | Parenteral / unspecified | Ennaid Therapeutics | 02 Apr 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Ennaid Therapeutics | Originator | USA |
| Ennaid Therapeutics | Owner | USA |
| University of Washington | Collaborator | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 02 Apr 2020 | Phase Change - Preclinical | Preclinical trials in Encephalitis in USA (Parenteral) before April 2020 [1] Updated 08 Apr 2020 |
| 02 Apr 2020 | Phase Change - Preclinical | Preclinical trials in Hepatitis C in USA (Parenteral) before April 2020 [1] Updated 08 Apr 2020 |
| 02 Apr 2020 | Phase Change - Preclinical | Preclinical trials in Yellow fever in USA (Parenteral) before April 2020 [1] Updated 08 Apr 2020 |
| 02 Apr 2020 | Phase Change - Suspended(Preclinical) | Suspended - Preclinical for Dengue in USA (Parenteral) for strategic diversion of focus on COVID-2019 therapeutic [1] Updated 08 Apr 2020 |
| 02 Apr 2020 | Phase Change - Suspended(Preclinical) | Suspended - Preclinical for Encephalitis in USA (Parenteral) for strategic diversion of focus on COVID-2019 therapeutic [1] Updated 08 Apr 2020 |
| 02 Apr 2020 | Phase Change - Suspended(Preclinical) | Suspended - Preclinical for Hepatitis C in USA (Parenteral) for strategic diversion of focus on COVID-2019 therapeutic [1] Updated 08 Apr 2020 |
| 02 Apr 2020 | Phase Change - Suspended(Preclinical) | Suspended - Preclinical for West Nile virus infections in USA (Parenteral) for strategic diversion of focus on COVID-2019 therapeutic [1] Updated 08 Apr 2020 |
| 02 Apr 2020 | Phase Change - Suspended(Preclinical) | Suspended - Preclinical for Yellow fever in USA (Parenteral) for strategic diversion of focus on COVID-2019 therapeutic [1] Updated 08 Apr 2020 |
| 02 Apr 2020 | Phase Change - Suspended(Preclinical) | Suspended - Preclinical for Zika virus infection in USA (Parenteral) for strategic diversion of focus on COVID-2019 therapeutic [1] Updated 08 Apr 2020 |
| 28 Mar 2020 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Chikungunya-virus-infections in USA (Parenteral) Updated 28 Mar 2020 |
| 28 Mar 2020 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Dengue in USA (Parenteral) Updated 28 Mar 2020 |
| 28 Mar 2020 | Phase Change - No development reported | No recent reports of development identified for preclinical development in West Nile virus infections in USA (Parenteral) Updated 28 Mar 2020 |
| 28 Mar 2020 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Zika-virus-infection in USA (Parenteral) Updated 28 Mar 2020 |
| 16 Feb 2016 | Phase Change - Preclinical | Preclinical trials in Chikungunya virus infections, Dengue, West Nile virus infection, and Zika virus infection in USA (Parenteral) Updated 17 Feb 2016 |
References
-
Ennaid Therapeutics Announces Development of ENU200, A New Antiviral Therapeutic for the Treatment of COVID-19.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG